Evidence map›Paper›PMID 31333456›Full record

ArticleFrontiers in pharmacology2019

Chinese Herbal Medicine Combined With EGFR-TKI in EGFR Mutation-Positive Advanced Pulmonary Adenocarcinoma (CATLA): A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial.

Lijing Jiao, Jianfang Xu, Jianli Sun, Zhiwei Chen, Yabin Gong, Ling Bi, Yan Lu, Jialin Yao, Weirong Zhu, Aihua Hou and 7 more

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in pharmacology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
32citing papers in PubMed, 4 pooled it
5.8field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

32 citing papers in PubMed, 4 syntheses or guidelines pooled it, 50 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Trial
  6. Trial
  7. Trial
  8. Article
  9. Article
  10. Review
  11. Article
  12. Pharmaceuticals (Basel, Switzerland) · 2024
    Article
  13. Article
  14. Article
  15. Review
  16. Article
  17. Article
  18. Article
  19. Article
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

17 authors at 12 institutions in 1 country.

Lijing JiaoInstitute of Clinical Immunology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jianfang XuDepartment of Oncology, Shanghai Pulmonary Hospital, Tongji University, Shanghai, China.
Jianli SunDepartment of Oncology, Longhua Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Zhiwei ChenLung Tumor Clinical Medical Center, Shanghai Chest Hospital, Shanghai Jiaotong University, Shanghai, China.
Yabin GongDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ling BiDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yan LuDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Jialin YaoDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Weirong ZhuDepartment of TCM, Ruijin Hospital, Shanghai Jiaotong University, Shanghai, China.
Aihua HouDepartment of Oncology, Yantai Hospital of Traditional Chinese Medicine, Yantai, China.
Gaohua FengDepartment of Oncology, Zhangjiagang Hospital of Traditional Chinese Medicine, Zhangjiagang, China.
Yingjie JiaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin, China.
Weisheng ShenDepartment of Oncology, Jiangsu Jianyin People's Hospital, Jiangyin, China.
Yongjian LiDepartment of Oncology, Suzhou Hospital of Traditional Chinese Medicine, Suzhou, China.
Ziwen ZhangDepartment of Oncology, Changshu No.2 People's Hospital, Changshu, China.
Peiqi ChenDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Ling XuDepartment of Oncology, Yueyang Hospital of Integrated Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China.
Yueyang Hospital · CNShanghai University of Traditional Chinese Medicine · CNChangshu No.1 People's Hospital · CNFirst Teaching Hospital of Tianjin University of Traditional Chinese Medicine · CNJiangyin People's Hospital · CNLonghua Hospital Shanghai University of Traditional Chinese Medicine · CNRuijin Hospital · CNShanghai Chest Hospital · CNSuzhou Traditional Chinese Medicine Hospital · CNTongji University · CNYantaishan Hospital · CNZhangjiagang First People's Hospital · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Chinese herbal medicinedrug resistanceEGFR activating mutationsEGFR-TKIpulmonary adenocarcinoma

Identifiers

PMID31333456
PMCPMC6614728
OpenAlexW2954449538

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.